Home » Stocks » UroGen Pharma

UroGen Pharma Ltd. (URGN)

Stock Price: $22.57 USD 1.53 (7.27%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 497.08M
Revenue (ttm) 372,000
Net Income (ttm) -130.37M
Shares Out 22.02M
EPS (ttm) -6.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $22.57
Previous Close $21.04
Change ($) 1.53
Change (%) 7.27%
Day's Open 20.89
Day's Range 20.75 - 22.65
Day's Volume 62,368
52-Week Range 13.12 - 35.21

More Stats

Market Cap 497.08M
Enterprise Value 372.72M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.02M
Float 18.84M
EPS (basic) -6.16
EPS (diluted) -6.15
FCF / Share -4.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.18M
Short Ratio 17.44
Short % of Float 16.90%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1,336.23
PB Ratio 3.16
Revenue 372,000
Operating Income -133.65M
Net Income -130.37M
Free Cash Flow -98.72M
Net Cash 124.35M
Net Cash / Share 5.65
Gross Margin 4.84%
Operating Margin -35,928.23%
Profit Margin -35,044.90%
FCF Margin -26,536.56%
ROA -39.74%
ROE -70.96%
ROIC -103.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$44.14*
(95.57% upside)
Low
25.0
Current: $22.57
High
59.0
Target: 44.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue0.021.138.1617.53-
Revenue Growth-98.4%-86.17%-53.46%--
Gross Profit0.02-0.687.5617.50-
Operating Income-109-77.18-19.950.80-12.41
Net Income-105-75.66-20.00-1.94-12.69
Shares Outstanding20.5315.759.722.312.30
Earnings Per Share-5.12-4.80-2.14-1.91-5.88
Operating Cash Flow-71.02-37.33-9.574.19-7.18
Capital Expenditures-0.33-0.56-0.27-0.70-0.30
Free Cash Flow-71.34-37.89-9.843.49-7.48
Cash & Equivalents14810273.0021.3617.98
Total Debt2.60----
Net Cash / Debt14510273.0021.3617.98
Assets20210475.5523.0619.39
Liabilities22.0913.477.046.753.11
Book Value18090.0968.5216.3116.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name UroGen Pharma Ltd.
Country United States
Employees 186
CEO Elizabeth Barrett

Stock Information

Ticker Symbol URGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: URGN
IPO Date May 4, 2017

Description

UroGen Pharma, a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.